dihydrotetrabenazine has been researched along with dihydroxyphenylalanine in 5 studies
| Studies (dihydrotetrabenazine) | Trials (dihydrotetrabenazine) | Recent Studies (post-2010) (dihydrotetrabenazine) | Studies (dihydroxyphenylalanine) | Trials (dihydroxyphenylalanine) | Recent Studies (post-2010) (dihydroxyphenylalanine) |
|---|---|---|---|---|---|
| 234 | 4 | 60 | 8,823 | 322 | 833 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stoessl, AJ | 1 |
| Brooks, DJ; Frey, KA; Marek, KL; Oakes, D; Paty, D; Prentice, R; Shults, CW; Stoessl, AJ | 1 |
| Doudet, DJ; Holden, JE | 1 |
| Ahlskog, JE; Albin, RL; Brooks, DJ; Carbon, M; Dhawan, V; Eidelberg, D; Fahn, S; Feigin, A; Guttman, M; Gwinn-Hardy, K; Holloway, R; Innis, R; Katz, RG; Kieburtz, K; Kish, SJ; Lange, N; Langston, JW; Marek, K; McFarland, H; Morin, L; Moy, C; Murphy, D; Oertel, WH; Oliver, G; Palesch, Y; Powers, W; Ravina, B; Seibyl, J; Sethi, KD; Sheehy, P; Shults, CW; Stoessl, AJ | 1 |
| Arbizu, J; Blesa, J; Collantes, M; Juri, C; Luquin, MR; Martí-Climent, JM; Obeso, JA; Peñuelas, I; Prieto, E; Quincoces, G; Richter, JA; Riverol, M; Rodriguez-Oroz, MC; Zubieta, JL | 1 |
3 review(s) available for dihydrotetrabenazine and dihydroxyphenylalanine
| Article | Year |
|---|---|
Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it?
Topics: Brain; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Fluorine Radioisotopes; Humans; Neural Pathways; Parkinson Disease; Severity of Illness Index; Substantia Nigra; Tetrabenazine; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2001 |
Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.
Topics: Animals; Basal Ganglia; Biomarkers; Cocaine; Diagnostic Imaging; Dihydroxyphenylalanine; Disease Progression; Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Neuropeptides; Parkinson Disease; Radiopharmaceuticals; Technology Assessment, Biomedical; Tetrabenazine; Tomography, Emission-Computed, Single-Photon; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2003 |
The role of radiotracer imaging in Parkinson disease.
Topics: Biomarkers; Biotransformation; Blood-Brain Barrier; Carbon Radioisotopes; Clinical Trials as Topic; Cocaine; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Forecasting; Humans; Iodine Radioisotopes; Neurons; Parkinson Disease; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Receptors, Dopamine; Substantia Nigra; Tetrabenazine; Tomography, Emission-Computed, Single-Photon | 2005 |
2 other study(ies) available for dihydrotetrabenazine and dihydroxyphenylalanine
| Article | Year |
|---|---|
Raclopride studies of dopamine release: dependence on presynaptic integrity.
Topics: Animals; Binding Sites; Brain; Carbon Radioisotopes; Dihydroxyphenylalanine; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Fluorine Radioisotopes; Macaca mulatta; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neuropeptides; Raclopride; Radioligand Assay; Receptors, Dopamine D2; Tetrabenazine; Tomography, Emission-Computed; Vesicular Biogenic Amine Transport Proteins | 2003 |
New MRI, 18F-DOPA and 11C-(+)-alpha-dihydrotetrabenazine templates for Macaca fascicularis neuroimaging: advantages to improve PET quantification.
Topics: Animals; Brain; Carbon Radioisotopes; Dihydroxyphenylalanine; Image Enhancement; Macaca fascicularis; Magnetic Resonance Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reference Values; Subtraction Technique; Tetrabenazine | 2009 |